Financial Data and Key Metrics Changes - In 2025, the company achieved a total delivery of 596,905 vehicles, representing a 103% increase year-over-year, marking two consecutive years of doubled deliveries [5][9] - The net profit for 2025 was CNY 540 million, with a gross profit margin of 14.5%, up by 6.1% from 8.4% in 2024 [6][8] - Total revenue exceeded CNY 64 billion, reflecting a 101.3% increase compared to the previous year [8] - Cash flow from operations surpassed CNY 12 billion, an increase of CNY 4.15 billion from 2024 [8] Business Line Data and Key Metrics Changes - The company reported that it is the only startup EV company in China with monthly sales exceeding 70,000 units [5] - The gross profit margin for Q4 2025 reached a record 15% [6][8] - The company launched three new B-series models and revamped existing models, contributing to sales growth [10][12] Market Data and Key Metrics Changes - By the end of 2025, the company had established a sales and service network covering 259 cities, an increase of 31 cities from the previous year [17] - The total export volume reached 100,000 units, with the company ranking first among BEV startups in exports [6][21] - The company has expanded its international presence, with significant operations in Europe, Asia-Pacific, and South America [21] Company Strategy and Development Direction - The company aims to enhance its in-house production capabilities to mitigate raw material price fluctuations and improve cost control [26][27] - Localization of production is a strategic focus, with plans for localized production in Spain for the B10 model [34] - The company is committed to developing smart driving technology in-house, aiming to be recognized as a Tier 1 brand in this area by the end of 2026 [62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sales targets for 2026, despite potential market fluctuations [50][51] - The company anticipates that geopolitical tensions and oil price volatility may accelerate the adoption of new energy vehicles in Europe [68] - Management emphasized the importance of customer satisfaction and service capabilities as key areas for improvement [18] Other Important Information - The company has received recognition for its ESG governance capabilities, achieving a high rating from MSCI for three consecutive years [23] - A strategic agreement was signed with FAW Group for joint development of new energy passenger vehicles [20] Q&A Session Summary Question: Raw materials price changes and impact on GP margin - Management acknowledged the impact of raw material price increases but emphasized that cost control measures would mitigate significant effects on gross profit margins [26][27] Question: Breakdown of revenue from services and sustainability - The CNY 2.72 billion revenue includes carbon credit revenue, license fees, and export-related revenues, with expectations for growth in these areas [28][29] Question: Overseas business and localization plans - The company plans to localize production in Spain, with only 1/4 of B10 sales being produced locally, while the rest will be exported [34] Question: Q1 GP margin estimates and sales expenses - Management indicated that Q1 GP margin would likely drop due to lower sales volume, but they expect no major impact from raw material price changes [42][43] Question: Inventory levels and product mix - Current inventory levels are maintained at around 1.5 to 2 months, with a target of 600,000 sales volume for 2026, aiming for a mix of 60% new models and 40% old models [76][79]

Financial Data and Key Metrics Changes - In 2025, the total vehicle sales reached 596,905 units, an increase of 103% compared to the previous year, marking two consecutive years of doubling deliveries [3][4] - The company achieved a net profit of CNY 540 million in 2025, breaking even and becoming profitable [4][5] - Revenue exceeded CNY 64 billion, up by 101.3% year-on-year, with a gross profit margin of 14.5%, an increase of 6.1% from 8.4% in 2024 [5][6] - Cash flow from operations exceeded CNY 12 billion, up by CNY 4.15 billion compared to 2024 [5][6] - Total cash balance reached CNY 37.8 billion, an increase of CNY 13.2 billion or 50.9% [4][5] Business Line Data and Key Metrics Changes - The company launched three new B-series models and revamped existing models, contributing to strong sales performance [7][8] - The C10 model achieved over 200,000 units sold within 18 months, while the B05 and B10 models also saw significant sales shortly after their launches [6][7] - The gross profit margin for Q4 2025 reached a record 15% [4][5] Market Data and Key Metrics Changes - Leapmotor ranked first among all EV startups in China for total exports, exceeding 100,000 units in 2025 [4][20] - The company expanded its sales and service network to cover 259 cities, an increase of 31 cities from the previous year [16] - By the end of 2025, Leapmotor International established 900 sales and service outlets globally, with over 800 in Europe and Asia-Pacific [20] Company Strategy and Development Direction - The company aims to enhance in-house production capabilities to mitigate raw material price fluctuations and improve cost control [25][26] - Leapmotor is focusing on localization for its production strategy, particularly in Europe, to adapt to geopolitical changes [30][31] - The company plans to continue investing in R&D, particularly in smart driving technology, with a commitment to in-house development [48][49] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving sales targets for 2026, despite potential market fluctuations [40] - The company anticipates that the demand for new energy vehicles will continue to grow, particularly in the European market due to rising oil prices [51] - Management emphasized the importance of maintaining a balance in inventory levels to optimize sales performance [56][57] Other Important Information - Leapmotor received recognition for its ESG governance capabilities, achieving a high rating from MSCI for three consecutive years [21][22] - The company signed strategic agreements with FAW Group and other partners to enhance collaboration in R&D and production [19][50] Q&A Session Summary Question: Impact of raw material price changes on gross profit margin - Management acknowledged the pressure from raw material price increases but emphasized that cost control measures would mitigate significant impacts on gross profit margin [25][26] Question: Breakdown of revenue from services and sustainability - The CNY 2.72 billion revenue includes carbon credit revenue, license fees, and export-related revenues, with expectations for growth in these areas [27][28] Question: Overseas business and localization plans - Management confirmed that only one-fourth of B10 sales would be localized in Europe, with the rest exported, and emphasized the importance of localization for global expansion [30][31] Question: Guidance for Q1 gross profit margin and sales expenses - Management indicated that Q1 gross profit margin would likely drop due to seasonal sales volume fluctuations, while sales expenses would increase in 2026 but decrease per vehicle [34][37] Question: Sales targets for domestic and overseas markets - The company maintained its sales target of 1 million units for 2026, with a focus on Brazil and other key South American markets [40][43]

Financial Data and Key Metrics Changes - In 2025, total revenue reached $959.5 million, a 61.4% year-over-year increase, with gross profit more than doubling [34] - Adjusted net profit was approximately $230.3 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [38] - The company recorded a loss of $532.4 million due to share loss and impairment from the investment in Legend Biotech [35][36] Business Line Data and Key Metrics Changes - GenScript Life Science Group revenue grew 14.8% year-over-year to $522.1 million, contributing significantly to overall growth [34] - ProBio achieved a remarkable 309.1% year-over-year growth to $388.7 million, largely due to the LaNova license deal [34] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [34] Market Data and Key Metrics Changes - North American and European markets contributed 38% of total revenue, indicating a notable increase in international footprint [41] - Orders from first-time clients in the Life Science Group grew over 34% year-over-year, reflecting strong market demand [9] - The U.S. market maintained steady growth, while Europe achieved over 30% growth in 2025 [10] Company Strategy and Development Direction - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform innovation and ecosystem expansion [46] - Strategic investments will be made in automation and digitalization to enhance operational efficiency and cost-effectiveness [46] - The company plans to strengthen its capabilities in business synergy, globalization, and automation as key focuses for 2026 [47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth trajectory of the GenScript Life Science Group, expecting revenue growth between 15% and 18% in 2026 [46] - The company noted that geopolitical uncertainties had a relatively minor impact on biopharmaceutical production capacity in 2025 [62] - Management highlighted the importance of maintaining market leadership and focusing on cost optimization to improve profitability [56] Other Important Information - GenScript achieved significant ESG milestones, including an upgrade to AA rating by MSCI and inclusion in the FTSE4Good index series [7] - The company reported a significant increase in R&D efficiency, achieving a 140% improvement and reducing project timelines to six months [32] Q&A Session Summary Question: Revenue recognition from LaNova deal - The company confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [51] Question: Profitability and gross profit margin decline - Management explained that slight fluctuations in gross profit margins were due to necessary investments for global expansion and product mix shifts, with expectations for improvement in 2026 [55][56] Question: Outlook for global market share amid geopolitical uncertainties - Management expressed optimism about the long-term prospects for CRO and CDMO, citing a rebound in global biopharmaceutical investment and improved capacity utilization in China [62] Question: Development strategy for Legend Biotech - Management highlighted Legend's significant progress and profitability, stating that it will continue to evaluate options to maximize shareholder value [73] Question: Strategy to mitigate customer concerns regarding regulatory scrutiny - The company clarified that it is not classified as a genomics or gene therapy-related company and will enhance transparency and compliance to address customer concerns [75]

Financial Data and Key Metrics Changes - In 2025, the total revenue reached $959.5 million, a 61.4% year-over-year increase, with gross profit more than doubling [33] - Adjusted net profit was approximately $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - Adjusted gross profit grew 12.5% year-over-year to $267.3 million, with an adjusted gross profit margin of 51.2% [39] Business Segment Data and Key Metrics Changes - The GenScript Life Science Group revenue grew 14.8% year-over-year to $522.1 million, with integrated gene-to-protein services accounting for nearly 65% of total revenue growth [33][38] - ProBio generated $388.7 million in total revenue, with a 21% organic growth excluding the LaNova deal [40] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Data and Key Metrics Changes - North American and European markets contributed 38% of total revenue, reflecting an enhanced international footprint [40] - Orders from first-time clients in the Life Science Group grew over 34% year-over-year, indicating strong market demand [9] - The Asia Pacific region, particularly Greater China, showed increased activities, contributing to overall growth [10] Company Strategy and Development Direction - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform innovation, ecosystem expansion, and automation [45] - Strategic investments will be made in differentiating technologies and operational efficiency improvements to enhance margins [54] - The company plans to expedite the establishment of commercial manufacturing capacity for sweet proteins, laying the foundation for international market expansion [46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the Life Science Group, anticipating revenue growth between 15% and 18% in 2026 [45] - The company noted that geopolitical uncertainties had a relatively minor impact on biopharmaceutical production capacity in 2025 [59] - Legend Biotech is expected to positively impact the company's financials in the long run, with its CAR-T franchise achieving profitability [70] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [7] - R&D investment increased significantly, with a focus on AI-powered molecular discovery and product optimization, achieving a 140% improvement in R&D efficiency [31] Q&A Session Summary Question: Revenue recognition from LaNova deal - The company confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong growth in the Life Sciences Group [50] Question: Profitability and gross profit margin decline - Management explained that gross profit fluctuations were due to necessary investments for global expansion and product mix shifts, with expectations for improved margins in 2026 through cost optimization and operational efficiency [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and a thriving trend in biotech R&D [59] Question: Development strategy for Legend Biotech - Management highlighted that Legend Biotech is a valuable asset, with significant progress expected to benefit the company's financials in the long run [70] Question: Strategy to mitigate customer concerns regarding regulatory scrutiny - The company clarified that it provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Financial Performance and Key Metrics - In 2025, the company achieved total revenue of $959.5 million, representing a 61.4% year-over-year increase, with gross profit more than doubling [33][34] - Adjusted net profit reached nearly $230 million, reflecting a 285% year-over-year growth from $59.8 million in FY 2024 [37] - The adjusted gross profit margin was stable at 51.2%, with adjusted gross profit growing 12.5% year-over-year to $267.3 million [39] Business Segment Performance - The GenScript Life Science Group generated revenue of $522.1 million, growing 14.8% year-over-year, and was identified as the growth engine and profit center [33][38] - ProBio reported total revenue of $388.7 million, with 21% organic growth excluding the LaNova deal, driven by strong customer demand for protein and antibody services [40][41] - Bestzyme's revenue grew by 7.9% year-over-year to $58 million, outperforming the industry average of 5% [33] Market Performance - The North American and European markets contributed 38% of total revenue, indicating a notable increase in the company's international footprint [41] - The Asia Pacific region, particularly Greater China, showed increased activity, contributing to the overall growth [10] Company Strategy and Industry Competition - The company aims to achieve high-quality growth while gradually improving profitability, focusing on platform leadership, ecosystem expansion, and automation-driven scale [44] - The strategy includes strengthening global partnerships, enhancing customer reach, and integrating new modalities into existing platforms [44] - The company is committed to maintaining its competitive edge through strategic investments in R&D and operational efficiency improvements [54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the long-term growth trajectory of the CRO and CDMO sectors, citing a rebound in global biopharmaceutical investment and financing [59] - The company anticipates revenue growth for the GenScript Life Science Group to be between 15% and 18% in 2026, with an adjusted gross margin expected to reach 52% [44] Other Important Information - The company achieved significant progress in sustainability, receiving an upgraded ESG rating to AA from MSCI and being included in the FTSE4Good index series [6] - The company reported a share loss of $310.4 million related to its investment in Legend Biotech, which is expected to improve as Legend's financial position strengthens [34][37] Q&A Session Summary Question: Revenue recognition from LaNova deal - Management confirmed that the second milestone payment from the LaNova deal was recognized in the second half of 2025, contributing to strong organic growth [48][50] Question: Profitability and gross profit margin decline - Management acknowledged slight fluctuations in gross profit margins due to investments in global expansion and emphasized a focus on cost optimization and operational efficiency to improve profitability [53][54] Question: Outlook for Life Sciences business amid geopolitical uncertainties - Management expressed a highly optimistic outlook for the CRO and CDMO sectors, noting a rebound in global biopharmaceutical investment and improved capacity utilization in China [59][62] Question: Future strategy for Legend Biotech - Management highlighted Legend Biotech's significant progress and profitability, stating that they are not planning to establish new biotech companies but will leverage existing platforms to accelerate drug discovery [64][66] Question: Mitigating customer concerns regarding regulatory scrutiny - Management clarified that the company provides raw materials to gene therapy companies and is enhancing transparency and compliance to address regulatory concerns [72]

Financial Data and Key Metrics Changes - The underlying profit increased by 9% to HKD 11.4 billion, driven by capital recycling and strong recurring profit in aviation [4] - The ordinary dividend increased by 13%, reflecting the company's strong financial health and available liquidity [4][9] - The recurring underlying profit was HKD 9.8 billion, up 5% from the previous year, supported by high demand for air travel [5] Business Line Data and Key Metrics Changes - Swire Properties' underlying profit increased by 27%, primarily due to gains from the disposal of non-core assets [9][16] - The aviation segment saw a 19% increase in profit, with HAECO achieving a 73% growth in recurring profit due to demand for maintenance services [6][29] - The beverage segment's recurring profit remained flat, with a solid performance in Hong Kong but challenges in Southeast Asia [21][24] Market Data and Key Metrics Changes - The Hong Kong office market maintained steady occupancy, benefiting from a flight to quality in new buildings [5][17] - Retail sales in Hong Kong are outperforming the market, indicating signs of recovery [17] - The Chinese Mainland saw a resilient performance in beverages, with a 1% increase in recurring profit despite market disruptions [22] Company Strategy and Development Direction - The company is focused on disciplined execution of a HKD 100 billion investment plan across core markets, particularly in the Chinese Mainland [18] - Swire Coca-Cola plans to invest over RMB 12 billion in production facilities and logistics infrastructure over the next decade [26] - The strategy includes capital recycling of non-core assets and focusing on long-term strategic investments [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about consumer sentiment improving in both the Chinese Mainland and Hong Kong [33] - The aviation sector is expected to grow, with new facilities enhancing operational efficiency [34] - Challenges remain in Southeast Asia due to economic softness and competition, but long-term prospects are viewed positively [34] Other Important Information - The company has a healthy liquidity position with HKD 64 billion in group liquidity and a gearing ratio of 20.6% [12] - Sustainability initiatives are progressing well, with significant reductions in water withdrawal and waste diversion [15] Q&A Session Questions and Answers Question: Regarding shareholder returns and dividend policy - Management indicated that the progressive dividend policy is expected to continue, with a payout ratio of at least 50% of recurring profit [39][40] - Share buybacks are part of the strategy but depend on market conditions and liquidity [41] Question: Key drivers for improvement in the beverage business in 2026 - Management highlighted improvements in consumer sentiment and a shift towards online channels as key drivers for growth in the Chinese Mainland [42] - Southeast Asia is expected to recover from short-term challenges, with a focus on capturing growth in emerging markets [42] Question: Impact of Middle East disruptions and healthcare investments - The primary impact from Middle East disruptions is on Cathay Pacific, with limited expected effects on other parts of the group [56] - Management is taking a long-term view on healthcare investments, focusing on operational fundamentals rather than short-term valuations [57][58] Question: EBITDA margin improvements across markets - Management sees potential for improving EBITDA margins in the Chinese Mainland and Southeast Asia through revenue growth management and product mix strategies [60]

Financial Data and Key Metrics Changes - The underlying profit increased by 9% to HKD 11.4 billion, driven by capital recycling and strong recurring profit in aviation [4] - The ordinary dividend rose by 13%, reflecting the company's strong financial health and available liquidity [4][12] - The recurring underlying profit was HKD 9.8 billion, up 5% from the previous year, supported by high demand for air travel [5] Business Line Data and Key Metrics Changes - Swire Properties' underlying profit increased by 27%, primarily due to gains from the disposal of non-core assets [16] - The aviation segment saw a 19% increase in recurring profit, with HAECO achieving a 73% growth in recurring profit due to demand for maintenance services [6][30] - The beverage division's recurring attributable profit was HKD 1.39 billion, broadly in line with the previous year, despite a challenging environment [21] Market Data and Key Metrics Changes - The Hong Kong office market maintained steady occupancy levels, benefiting from a flight to quality trend [5] - In the Chinese mainland, the beverage segment's recurring profit increased by 1%, while Hong Kong's performance strengthened with a 14% rise in recurring profit [22] - The Vietnam and Cambodia markets faced a 35% decrease in attributable recurring profit due to a difficult operating environment [24] Company Strategy and Development Direction - The company continues to focus on disciplined execution of its HKD 100 billion investment plan across core markets, particularly in the Greater Bay Area [2][18] - Swire Coca-Cola plans to invest over RMB 12 billion in production facilities and logistics infrastructure over the next decade [26] - The strategy includes capital recycling of non-core assets and exiting underperforming businesses to enhance overall returns [11][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving consumer sentiment in both the Chinese mainland and Hong Kong, anticipating a positive contribution from residential projects [34] - The aviation sector is expected to grow, with Cathay Pacific planning to expand capacity and frequency [36] - Challenges remain in Southeast Asia, particularly in Thailand, due to economic softness and competition [35] Other Important Information - The company reported a healthy liquidity position with HKD 64 billion in group liquidity and a gearing ratio of 20.6% [12] - Sustainability initiatives are progressing well, with significant reductions in water withdrawal and waste diversion [15] Q&A Session Summary Question: Shareholder return and dividend policy - Management indicated confidence in the progressive dividend policy, expecting mid-single-digit constant improvement barring significant disruptions [40][41] Question: Beverage business improvement drivers for 2026 - Management highlighted improving consumer sentiment and structural changes in purchasing channels as key drivers for the beverage business in 2026 [43][44] Question: Impact of Middle East disruptions and healthcare investment updates - Management noted that the primary impact from Middle East disruptions is on Cathay Pacific, with no significant effects expected on other parts of the group [58] - The healthcare investment strategy remains focused on long-term fundamentals, with patience emphasized in navigating high valuations [59]

Financial Data and Key Metrics Changes - The underlying profit increased by 9% to HKD 11.4 billion, driven by capital recycling and strong recurring profit in aviation [4] - The recurring underlying profit was HKD 9.8 billion, up 5% from last year, supported by high demand for air travel and resilient performance in property and beverages [6] - The gearing ratio improved to 20.6%, with net debt down 8% to HKD 65 billion [13] Business Line Data and Key Metrics Changes - Swire Properties' underlying profit rose by 27%, primarily due to gains from the disposal of non-core assets [17] - Aviation saw a 19% increase in underlying profit, with HAECO achieving a 73% growth in recurring profit due to demand for maintenance services [6][32] - The beverage segment reported a flat recurring profit, with a notable 14% increase in Hong Kong, while Vietnam and Cambodia saw a 35% decrease in profit [23][24][25] Market Data and Key Metrics Changes - The Hong Kong office market maintained steady occupancy, benefiting from a flight to quality trend [5] - In the Chinese mainland, attributable gross rental income grew at a CAGR of 10% over the past decade [18] - The beverage market in the Chinese mainland remained resilient, with a 1% increase in recurrent profit despite significant disruptions [24] Company Strategy and Development Direction - The company is focused on disciplined execution of a HKD 100 billion investment plan across core markets, particularly in the Greater Bay Area [2][20] - Swire Coca-Cola plans to invest over RMB 12 billion in production facilities and logistics infrastructure over the next decade [28] - The strategy includes capital recycling of non-core assets and enhancing operational efficiency across all divisions [12][14] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about improving consumer sentiment in both the Chinese mainland and Hong Kong, anticipating a positive contribution from residential projects [36] - The aviation sector is expected to grow, with new facilities enhancing operational efficiency [37] - Challenges remain in Southeast Asia, particularly in Thailand, due to economic softness and competition [37] Other Important Information - The company has made significant progress in sustainability, achieving various targets ahead of schedule [16] - The beverage segment is adapting to structural changes in purchasing channels, focusing on online sales and operational efficiency [46] Q&A Session Summary Question: Shareholder return and dividend policy - Management confirmed a commitment to a progressive dividend policy, expecting mid-single-digit growth, and indicated that share buybacks are part of their strategy [40][43][44] Question: Beverage business improvement drivers for 2026 - Management highlighted improving consumer sentiment and structural changes in purchasing channels as key drivers for expected improvements in 2026 [46][48] Question: NAV discount and healthcare business updates - Management acknowledged the NAV discount issue and emphasized a long-term approach to healthcare investments, focusing on operational fundamentals rather than short-term valuations [50][61]

Financial Data and Key Metrics Changes - Recurrent business profit for 2025 exceeded HKD 5.6 billion, representing a year-on-year decline due to changes in travel patterns and the overall economic environment [4][27] - Total net profit attributable to shareholders for the year was HKD 14.7 billion, including property development profit of HKD 11 billion, resulting in an underlying business profit of HKD 16.7 billion [13] - The average borrowing cost for 2025 was 3.5%, which is 0.2 percentage points lower than the previous year [17] Business Line Data and Key Metrics Changes - Railway operations remained the core business, with total local patronage exceeding 1.9 billion, maintaining passenger journeys on time at 99.9% [5][27] - Cross-boundary services to Lo Wu and Lok Ma Chau recorded over 8% growth, while High Speed Rail patronage increased by over 16% [5][28] - Station commercial EBIT decreased by 3% due to negative rental reversion and lower telecommunications revenue [14] Market Data and Key Metrics Changes - The patronage of the High Speed Rail Hong Kong section exceeded 30 million last year, marking a year-on-year increase of over 16% [5][28] - Despite a challenging retail environment, shopping malls recorded near full occupancy, reflecting business resilience [6][28] Company Strategy and Development Direction - The company is focused on new railway construction, ensuring service quality, and developing new growth drivers while reinforcing financial sustainability [20][31] - The corporation has committed HKD 65 billion over five years for railway asset renewal and maintenance, with approximately HKD 47 billion already invested [20][32] - The company is leveraging technology, including AI and big data, to enhance customer experience and operational efficiency [21][32] Management's Comments on Operating Environment and Future Outlook - The management acknowledged challenges due to a changing global economic landscape and evolving local travel patterns but emphasized substantial opportunities ahead [20][31] - The outlook for 2026 is cautiously optimistic, with expectations to tender new projects subject to market conditions [26][35] Other Important Information - The board proposed a final ordinary dividend of HKD 0.89 per share, bringing the total ordinary dividend for the year to HKD 1.31 [19][31] - The company is actively supporting community development, with initiatives exceeding HKD 15 billion in community benefits [25][35] Q&A Session Summary Question: What are the key challenges and opportunities for the company moving forward? - The company highlighted the need to navigate a changing economic landscape while focusing on new railway construction and service quality [20][31] Question: How is the company planning to enhance customer experience? - The company is leveraging technology, including AI and virtual service ambassadors, to improve customer interactions and operational efficiency [21][32]

Financial Data and Key Metrics Changes - Recurrent business profit for 2025 exceeded HKD 5.6 billion, representing a year-on-year decline due to changes in travel patterns and the overall economic environment [3][25] - Total net profit attributable to shareholders for the year was HKD 14.7 billion, including property development profit of HKD 11 billion, leading to an underlying business profit of HKD 16.7 billion [12][28] - The average borrowing cost for 2025 was 3.5%, which is 0.2 percentage points lower than the previous year [16] Business Line Data and Key Metrics Changes - Railway operations remain the core business, with local patronage exceeding 1.9 billion and passenger journeys on time maintained at 99.9% [4][25] - Cross-boundary services to Lo Wu and Lok Ma Chau recorded over 8% growth, while High Speed Rail patronage increased by over 16% [4][26] - Station commercial EBIT decreased by 3%, primarily due to negative rental reversion and lower telecommunications revenue [13] Market Data and Key Metrics Changes - The patronage of the High Speed Rail Hong Kong section exceeded 30 million last year, marking a new annual record since commissioning [4] - Near full occupancy was recorded in shopping malls despite a challenging retail environment, reflecting business resilience [5][26] - The number of direct access destinations from Hong Kong West Kowloon Station increased to 110 [4][26] Company Strategy and Development Direction - The company is focused on new railway construction, ensuring service quality, and developing new growth drivers while reinforcing financial sustainability [18][30] - Six new railway projects are progressing, with Kwu Tung Station expected to be commissioned next year [6][27] - The company is leveraging technology, including AI and big data, to enhance customer experience and optimize cost efficiency [19][31] Management's Comments on Operating Environment and Future Outlook - The management expressed cautious optimism for 2026, anticipating a gradual recovery of the global economy and focusing on strengthening core capabilities [24][30] - The company highlighted the importance of asset renewal and maintenance, committing HKD 65 billion over five years for railway asset renewals [18][31] - The management emphasized the need for early preparations for investments exceeding HKD 100 billion across multiple projects [9][27] Other Important Information - The board proposed a final ordinary dividend of HKD 0.89 per share, bringing the total ordinary dividend for the year to HKD 1.31 [17][30] - The company is actively supporting community development, providing fare concessions and exceeding HKD 15 billion in community benefits [23][34] - The corporation is committed to environmental sustainability, setting internationally recognized carbon reduction targets [34] Q&A Session Summary Question: What are the key challenges and opportunities for the company moving forward? - The management acknowledged challenges due to changing economic conditions but highlighted substantial opportunities in new railway projects and technological advancements [24][30] Question: How is the company addressing the evolving travel and consumption patterns? - The company is enhancing customer experience through marketing initiatives and collaborations with event organizers [5][26] Question: What is the company's approach to financial management amid substantial investment requirements? - The management stated that the company will continue to undertake financing initiatives and prudently plan for future cash flow needs [21][33]